London (www.aktiencheck.de, Anzeige)
EinschätzungStrong OutperformerKurszieleKursziel 12M: 2,50 EUR
Kurschance: 102%
Kursziel 24M: 3,50 EUR
Kurschance: 182%StammdatenISIN: GB00BM9XQ619
WKN: A3DTUQ
Ticker: T9G.HMKursdatenKurs: 1,240 EUR
52W Hoch: 1,630 EUR
52W…
…
Pro Research: Wall Street dives into Amgens diverse biopharma strategies…
Minneapolis (www.aktiencheck.de) - Rating-Update:
Die Analysten von Piper Sandler belassen die Aktie von Amgen Inc. (ISIN: US0311621009, WKN: 867900, Ticker-Symbol: AMG,…
Wall Street has been focused on Novo Nordisk, Eli Lilly and other large drugmakers hoping to join the weight loss…
Eli Lilly, Novo Nordisk, Amgen and AstraZeneca are included in this Analyst Blog.…
…
Xeris (XERS) gains 16% after signing a licensing deal with Amgen, which allows the latter to utilize the XeriJect technology…
Xeris Biopharma Holdings (NASDAQ:XERS) announced an exclusive worldwide license agreement with Amgen for the development, manufacturing, and...…
An der US-amerikanischen Börse notiert die Amgen-Aktie derzeit ein wenig leichter. Das Wertpapier kostete zuletzt 307,15 US-Dollar. Ein Minus von…
…
Nvidia is doubling down on artificial-intelligence-powered drug discovery and development, announcing expanded partnerships with Amgen and Recursion Pharmaceuticals.…
Dublin, Jan. 05, 2024 (GLOBE NEWSWIRE) -- The "Global Antibody Therapeutic Market: Focus on Format, Disease Area, Route…
Kulmbach (www.aktiencheck.de) - Amgen-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von…
Die Aktien der amerikanischen Biotech-Riesen Vertex Pharmaceuticals, Amgen und Regeneron haben einen bärenstarken Start ins Börsenjahr 2024 hingelegt. Alle drei…
Amgen 1.85% TomTrades (EMT01): $AMGN sieht aus als würde es ausbrechen, mit gutem Volumen und einer starken Performance, vor allem…
ach dem ernüchternden Jahresstart vor allem für Technologiewerte haben die US-Börsen auch am Mittwoch nachgegeben. Die Veröffentlichung des jüngsten Sitzungsprotokolls…
Amgen Inc (NASDAQ:AMGN, ETR:AMG) stock is poised to move higher in 2024 on a thesis its Phase II drug AMG133…
Der Anteilsschein von Amgen notiert heute etwas fester. Das Papier kostete zuletzt 286,19 US-Dollar. Freuen können sich gegenwärtig die Aktionäre…
…
Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients…
…
Tokio (www.aktiencheck.de) - Rating-Update:
Narumi Nakagiri, Analyst von Daiwa Capital Markets, stuft die Aktie von Amgen Inc. (ISIN: US0311621009, WKN: 867900,…
Dublin, Dec. 19, 2023 (GLOBE NEWSWIRE) -- The "Biologics Drug Discovery Market - A Global and Regional Analysis,…
…
Toronto (www.aktiencheck.de) - Amgen-Aktienanalyse von BMO Capital Markets:
Evan Seigerman, Analyst von BMO Capital Markets, stuft in einer aktuellen Aktienanalyse die…
Amgen lifted at BMO Capital as analysts see 22% potential upside…
These are the stocks posting the largest moves in premarket trading.…
Intel 0.31% Silberpfeil60 (BLKCHN): Intel sagt, dass Dutzende von PC-Herstellern seinen neuen KI-fähigen Chip verwenden Intel https://de.tradingview.com/symbols/NASDAQ-INTC/ sagte am Donnerstag,…
…
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Breast Cancer Drugs Global Market Report 2024" has been added…
New York (www.aktiencheck.de) - Rating-Update:
Die Analysten von Morgan Stanley stufen die Aktie von Amgen Inc. (ISIN: US0311621009, WKN: 867900, Ticker-Symbol:…
Amgens (AMGN) BLA for tarlatamab to treat advanced small cell lung cancer gets FDAs priority review. A decision is expected…
The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen.…
This year the NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has slowly tracked downward in response to the high volatility seen across global…
…
Amgen Inc. AMGN said late Tuesday its board has authorized a dividend of $2.25 a share, up from $2.13 a…
…
IBM, Nike, Amgen and Salesforce are catalysts as Dow industrials pivot to gain…
Toronto (www.aktiencheck.de) - Amgen-Aktienanalyse von RBC Capital Markets:
Gregory Renza, Analyst vom Investmenthaus RBC Capital Markets, stuft die Aktie von Amgen…
RBC Capital upgrades Amgen on improving position of stability and diminishing uncertainty…
By David Bautz, PhD
NASDAQ:ARWR
READ THE FULL ARWR RESEARCH REPORT
Business Update
Updated Clinical Data for Cardiometabolic Candidates Presented at AHA 2023
On November…
Companies covered in this report are Amgen, Boehringer Ingelheim, BridgeBio Pharma, Erasca, Innovent Biologics Inc., Incyte, Mirati Therapeutics, Novartis, Jemincare,…
Major multiple myeloma market players include Amgen Inc., Johnson & Johnson, Takeda Pharmaceuticals Company Limited, Novartis AG, Sanofi, Teva Pharmaceuticals…
The Global Melanoma Therapeutics Market Size was valued at USD 5.03 Billion in 2022 and the Worldwide Melanoma Therapeutics Market…
Pro Research: Wall Street takes on Amgens diverse prospects…
Amazons (AMZN) AWS gets selected by Amgen. This highlights the efficiency and reliability of AWS innovative cloud products and services.…
…
Key pancreatic cancer market players include Amgen Inc., Novartis AG, Pfizer Inc., Aduro Biotech Inc., Clovis Oncology Inc., NewLink Genetics…
Companies covered in this report are AbbVie Inc., Sanofi, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La…